GlaxoSmithKline: Herpes Genitalis trials

The registry lists 11 Herpes Genitalis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 1Phase 3 1Phase 4 4No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital HerpesCompletedNCT05298254Phase 1/2Results posted
• VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2CompletedNCT00306293Phase 4Results posted
• A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.CompletedNCT00158860Phase 4Results posted
• VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.CompletedNCT00116844Phase 4Results posted
• An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.CompletedNCT04950712
• Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)CompletedNCT01390805
• A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected PersonsTerminatedNCT00079911Phase 4
• A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected PatientsStatus unknownNCT00005663Phase 3
• The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected PatientsCompletedNCT00002404Not applicable
• A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected PatientsCompletedNCT00002084Not applicable
• A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected PatientsCompletedNCT00002000Not applicable